Yibin Xiang

This inventor holds 21 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Genzyme Corporation, Genetics Institute, Inc., Taigen Biotechnology. Active years: 2002-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yibin Xiang. Retrieved from https://idiyas.com/inventor/yibin-xiang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 10)

% Patents Active = 38.1

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 10)

Average Co-Inventor Count = 8.5

ph-index = 8

Forward Citations = 331(Granted Patents)

Location History:

Waltham, MA (US) (2014)
Acton, MA (US) (2002 - 2017)
Dracut, MA (US) (2018 - 2024)

Company Filing History:

Genetics Institute, Inc.

Taigen Biotechnology Company, Ltd.

Massachusetts Institute of Technology

patents

where one patent can have more than one assignee

Years Active: 2002-2024

Loading Chart...

Areas of Expertise:

Glucosylceramide Synthase Inhibitors

NAMPT Inhibitors

Polyamine Compounds

Protease Inhibitors

Aminoquinoline Compounds

Phospholipase Enzyme Inhibitors

2-Acylaminopropoanol

Coronaviral Proteases

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12060349 - Glucosylceramide synthase inhibitors (2024-08-13),

2. 11008316 - Glucosylceramide synthase inhibitors (2021-05-18),

3. 10017523 - NAMPT inhibitors and methods (2018-07-10),

4. 9745294 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2017-08-29),

5. 9744153 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2017-08-29),

6. 9272996 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2016-03-01),

7. 8980926 - 2-aminoindole compounds and methods for the treatment of malaria (2015-03-17),

8. 8940776 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2015-01-27),

9. 8633168 - Inhibitors of S-adenosyl-L-methionine decarboxylase (2014-01-21),

10. 8309593 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2012-11-13),

11. 8304447 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2012-11-06),

12. 7501526 - Synthesis of polyamine compounds (2009-03-10),

13. 7462594 - Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases (2008-12-09),

14. 7399776 - Polyamine compounds for treating chemokine receptor mediated diseases (2008-07-15),

15. 7378524 - Aminoquinoline compounds (2008-05-27),

Title: The Innovative Contributions of Yibin Xiang in the Field of Pharmaceuticals

Introduction

Yibin Xiang, based in Acton, MA, has made significant strides in the pharmaceutical industry with a remarkable portfolio of 21 patents. His inventions primarily focus on the treatment of metabolic diseases, positioning him as a key innovator in the development of therapeutic solutions.

Latest Patents

Among his latest innovations are the glucosylceramide synthase inhibitors. These inventions center around inhibitors of glucosylceramide synthase (GCS) represented by specific structural formulas, which are essential for the treatment of metabolic diseases such as lysosomal storage diseases. Furthermore, these inhibitors have applications in cancer treatment, either used alone or in combination with enzyme replacement therapy.

Career Highlights

Yibin Xiang has had a distinguished career, contributing his expertise at prominent companies such as Genzyme Corporation and Genetics Institute, Inc. His work in these organizations has not only advanced his own research but also contributed to the broader field of pharmaceuticals.

Collaborations

Throughout his career, Yibin has collaborated with notable individuals in the industry, including coworkers Cassandra Celatka and Craig S. Siegel. These partnerships have likely facilitated the innovative advancements and successful patent applications that he is known for.

Conclusion

Yibin Xiang's dedication to innovation in pharmaceutical research is reflected in his numerous patents and collaborative efforts. His work, particularly with glucosylceramide synthase inhibitors, demonstrates his commitment to addressing critical health challenges. As the field continues to evolve, his contributions will undoubtedly have a lasting impact.

Profile summary based on public USPTO records.